Mitapivat Maintains Safety, Tolerability Over 2 Years in Sickle Cell Disease

Extension analysis from a phase 1 trial show the investigative oral mitapivat was not associated with any discontinuations nor deaths over 2 years.

Related Keywords

San Diego ,California ,United States ,American , ,National Institutes Of Health ,Sickle Cell Branch Of The National Heart ,Lung Blood Institute ,American Society Of Hematology ,Swee Lay Thein ,American Society ,National Institutes ,Sickle Cell Branch ,National Heart ,Blood Institute ,Sickle Cell Disease ,Mscd ,Sickle Cell ,Mitapivat ,Phase 1 ,Findings ,Safety ,Tolerability ,Cash ,Mash 2023 ,